- Fovia Ai
AMSTERDAM and CHICAGO, Nov. 27, 2017 /PRNewswire/ -- Royal Philips (NYSE: PHG, AEX: PHIA), a global leader in health technology, today unveiled the IQon Elite Spectral CT to provide clinicians with increased diagnostic certainty in every scan, with zero compromise. The IQon Elite Spectral CT, a new configuration of the world's first spectral detector-based computed tomography (CT) scanner, debuts a suite of features that will enhance the clinical benefits of the IQon platform to improve diagnostic confidence while enhancing the patient experience, and supporting the needs of emergency/trauma and oncology care.
"The IQon Elite Spectral CT is the first detector-based spectral CT of its kind to deliver more confident patient diagnoses in the first scan, representing a revolution in CT performance," said Kees Wesdorp, Business Leader, Diagnostic Imaging, Philips. "With the IQon Elite, Philips is elevating its already high standard of patient care by providing health systems with a more sophisticated level of data and higher throughput capability that is exceptional in the healthcare industry."
Pioneering a new spectral standard of care
Representing an evolution of the original IQon Spectral CT scanner, the IQon Elite advances the capabilities of its predecessor through a series of key benefits that support emergency/trauma department care and Philips' commitment to oncology excellence. This new configuration provides a number of enhanced features and benefits, including:
The IQon Elite Spectral CT scanner will be available globally during the first quarter of 2018. For more information about Philips IQon Spectral CT and the Philips Spectral Diagnostic Suite, including clinical images demonstrating the spectral difference, please visit: http://www.spectralctlearningcenter.philips.com/.
Philips will be showcasing the new IQon Elite Spectral CT alongside its full portfolio of integrated imaging systems, devices, informatics and services at booth #6735 in Hall B at McCormick Place. For more information about Philips' presence at RSNA, please visit www.philips.com/rsna, and follow @PhilipsLiveFrom for #RSNA17 live updates throughout the event.
 Results from case studies are not predictive of results in other cases. Results in other cases may vary.
 Typical protocol includes 600 images per SBI, 3 conventional series per patient, and 1.5 SBI per patient
For further information, please contact:
Philips Group Press Office
Tel.: +31 6 10888824
About Royal Philips
Royal Philips (NYSE: PHG, AEX: PHIA) is a leading health technology company focused on improving people's health and enabling better outcomes across the health continuum from healthy living and prevention, to diagnosis, treatment and home care. Philips leverages advanced technology and deep clinical and consumer insights to deliver integrated solutions. Headquartered in the Netherlands, the company is a leader in diagnostic imaging, image-guided therapy, patient monitoring and health informatics, as well as in consumer health and home care. Philips' health technology portfolio generated 2016 sales of EUR 17.4 billion and employs approximately 73,000 employees with sales and services in more than 100 countries. News about Philips can be found at www.philips.com/newscenter.
SOURCE Royal Philips